SubHero Banner
Text

 

Ready to realize your brand’s full potential? So are we.

Meet with our team during ID Week to learn how our HEOR solutions are advancing life sciences to improve clinical care and outcomes.

Request a meeting

Horizontal Rule

Event Contributions

Accordion Block
  • Session 56: HAI: MDRO – GNR Treatment

    12:15–1:30 p.m., Exhibit Hall BC

    Treatment Patterns of Hospitalized Adults with Infections Due to Carbapenem Non-susceptible Gram-negative Organisms in a Large Electronic Health Record Database in the U.S. (517)

    Burton T1, Anderson A1, Seare J1, Dillon R2, McCann E2

    1Optum Services, Inc., Eden Prairie, MN, USA; 2 Merck & Co., Inc., Kenilworth, NJ, USA

    ADD TO CALENDAR

     

    Session 69: What's New in Clinical Practice?

    12:15–1:30 p.m., Exhibit Hall BC

    Identifying Opportunities to Improve Adherence to Sepsis Care Guidelines Compliance (785)

    Balankura T1, Odom A1

    1Optum Services, Inc., Eden Prairie, MN, USA

    ADD TO CALENDAR

    OR
  • Rapid Fire Poster Session: Vaccines

    12:25–12:30 p.m., Hall BC - Arena 1

    Meningococcal vaccination among patients newly diagnosed at high-risk for meningococcal disease in the U.S. (2726)

    Bengtson LGS1, Marshall GS2, Buikema AR1, Koep E1, Novy P3, Hogea CS3

    1Optum Life Sciences, Inc., Eden Prairie, MN 55344, USA; 2University of Louisville, Louisville, KY 40202, USA; 3 GSK, Philadelphia, PA 19112, USA

    ADD TO CALENDAR

     

    Session 277: Vaccines – Bacterial

    12:15–1:30 p.m., Exhibit Hall BC

    Meningococcal vaccination among patients newly diagnosed at high-risk for meningococcal disease in the U.S. (2726)

    Bengtson LGS1, Marshall GS2, Buikema AR1, Koep E1, Novy P3, Hogea CS3

    1Optum Life Sciences, Inc., Eden Prairie, MN 55344, USA; 2University of Louisville, Louisville, KY 40202, USA; 3 GSK, Philadelphia, PA 19112, USA

    ADD TO CALENDAR

     

    Session 278: Vaccines – Influenza

    12:15–1:30 p.m., Exhibit Hall BC

    Relative Vaccine Efficacy of High-Dose versus Standard Dose Influenza Vaccines in Preventing Probable Influenza in a U.S. Medicare Fee-For-Service Population (2747)

    Paudel M1, Mahmud SM2,3, Buikema A1, Korrer A1, Van Voorhis D1, Brekke L1,  Chit A4,5

    1Optum Life Sciences, Inc., Eden Prairie, Minnesota, USA; 2Department of Community Health Sciences, College of Medicine, University of Manitoba, Winnipeg, MB, Canada; 3George & Fay Yee Center for Healthcare Innovation, University of Manitoba/Winnipeg Regional Health Authority, Winnipeg, MB, Canada; 4Sanofi Pasteur, Swiftwater, PA, USA; 5Leslie Dan School of Pharmacy, University of Toronto, Toronto, ON, Canada

    ADD TO CALENDAR

    OR